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Abstract 
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive molecule expressed in some subsets of 
normal and neoplastic cells.  Mature human dendritic cells (DCs)  have been shown to express IDO1, but 
little is known about its expression and function during DC differentiation from bone marrow (BM) 
hematopoietic stem/progenitor cells (HSPCs). Here, we show that during in vitro differentiation along 
myeloid DC lineage CD34
+
 HSPCs acquire IDO1 expression, which acts in a tolerogenic manner by 











 HPSC-derived DCs expressed IDO1, Langerin, CD11b, and CD1c. Cell sorting experiments 






 cells, expressing CD103, 
which is capable of inducing Tregs through an IDO1-dependent manner. In conclusion, DC differentiation 
from CD34
+





CD103-expressing DCs. These data point toward IDO1 expression as part of a tolerogenic signature during 
DC development.  
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Introduction 
Dendritic cells (DCs) are rare, heterogeneous professional antigen-presenting cells (APCs), which regulate 
the balance between immunity and tolerance, thus critically directing antigen (Ag)-specific immune response 
[1]. In addition to their classical and well-established function as initiator of immune response, more recent 
studies focused on the role and function of tolerogenic DCs, which are important in the induction and 
maintenance of peripheral immune tolerance through a variety of mechanisms, including the generation, de 
novo, of T regulatory cells (Tregs) [1,2].
  
Both immunogenic and tolerogenic DCs arise from hematopoietic 
stem/progenitor cells (HSPCs) in the bone marrow (BM) through specialized myeloid and lymphoid 
progenitor subsets [3].
 
Although it is clear that DC function is influenced within peripheral tissues by 
inflammatory microenvironment, which may switch activatory into immunoregulatory DCs and vice versa 
[4], it remains to be elucidated whether during DC lineage differentiation BM precursors become committed 
to tolerogenic or activatory DCs. Particularly, it remains unknown whether specific functional pathways are 
expressed and activated at the level of BM DC precursors. Human CD34
+
 HSPCs may in vitro differentiate 









 for dermal or interstitial DCs 
(DDC-IDCs).  





 DCs have been shown to play a dual role in Ag presentation, thus 





Altogether, these findings indicate CD103
+ 
DCs as important regulators of 
immune response [9]. 
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the initial rate-limiting step of tryptophan degradation 
along the kynurenine pathway [10].
 
Both tryptophan starvation and the products of tryptophan catabolism 
negatively regulate T-cell proliferation and survival [10,12].
 
The role of IDO1 as immunosuppressive agent 
in different settings is well-established [12,14].
 
In particular, IDO1-expressing DCs have a tolerogenic effect 
on T cell-based adaptive immune response by expanding/inducing Tregs [14,15].
 
In humans, although several 
investigators have recently reported about IDO1 expression in monocyte-derived DCs (Mo-DCs) [16-18], no 
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data are currently available about the expression and function of IDO1 during DC differentiation from 
human CD34
+
 HSPCs.  
In this report, for the first time, we show that CD103 marks a subset of IDO1-expressing Langerin
+
DCs 
obtained during in vitro DC differentiation.  
 
Materials and Methods 
Cell isolation 
All samples were obtained from healthy donors after informed consent was signed. Mononuclear cells 
(MNCs) were isolated from buffy coats, mobilized peripheral blood (PB), BM and cord blood (CB) by 





cells were purified from the MNC fraction by Mini or Large Macs high-gradient magnetic separation 
column (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of  cell populations was always > 
90%. CD103
+
 cells  were purified by cell-sorting from the CD34
+
-derived immature DCs after 7 days of 
culture, as previously described [19] .
 
The purity of CD103
+




 cells only from mobilized PB were cultured (10
5
 cells/ml) in RPMI 1640 (BioWhittaker, 
Walkersville, MD, USA) containing 10% BSA (Sigma Aldrich, St. Louis, MO, USA) with L-glutamine and 
antibiotics (10%-RPMI), hereafter referred as medium, supplemented with 50 ng/ml of granulocyte 
macrophage-colony stimulating factor (GM-CSF; Peprotech, Rocky Hill, NJ, USA), 10 ng/ml of tumor 
necrosis factor (TNF)-α (Endogen, Rockford, IL, USA) and 50 ng/ml of Fms-related tyrosine kinase 3 ligand 
(FLT3L; eBioscience, San Diego, CA, USA) for 7 days [20]. CD34
+
-derived DCs were harvested after 7 
days of culture, and used for the purification of CD1a
+
 cells by using CD1a microbeads (Miltenyi Biotec). 
CD1a
-




 cell population by using CD14 
microbeads (Miltenyi Biotec).  
 
Flow cytometry 
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Flow cytometry cell analyses were performed by FACSCanto
TM 
II flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA). DCs subsets were determined using the following anti-human monoclonal 
antibodies (mAbs): allophycocyanin (APC)-conjugated CD1a, CD14 and CD86 (Biolegend, San Diego, CA, 
USA; clones HI149, HCD14, IT2.2 and 67A4); phycoerydhrin (PE)-conjugated CD103, CD80 and CD83 
(Biolegend; LF61, 2D10 and HB15e); fluorescein isothiocyanate (FITC)-conjugated CD103 and HLA-DR 
(eBioscience, San Diego, CA, USA; B-Ly7 and L243); phycoerythrin-cyanin 7 (PeCy7)-conjugated CD11b 
(eBioscience, ICRF44) and CD1c (Biolegend, L161) and PE-conjugated Langerin (R&D systems, 







/well) were cultured in medium with allogeneic CD3
+
 T cells (1.5x10
5
/well) in 
96-well plates with or without the IDO1 inhibitor 1-methyl tryptophan-levo (1-MT-L). After 5 days, T cells 
were harvested and stained using FOXP-3 intracellular staining kit (eBioscience) including PE-conjugated 
anti-human FOXP3 (PCH101), FITC-conjugated CD4 (RPA-T4) and APC-conjugated CD25 (BC96) mAbs.  
CellTiter 96AQueous One Solution Cell Proliferation Assay (Promega, WI, USA) was used to detect the 
proliferation effect of DCs on CD3
+




/well) were incubated in 96-
well microplates with irradiated (3000 cGy) DCs (3x10
3
) with or without 1-MT-L. After 6 days, CellTiter 
96AQueous One Solution reagent (Promega) was added to each well and the microplate was incubated for 
additional 4 h. The OD value was measured in triplicate wells with an ELISA plate reader (Multiskan Ex; 


















immature DCs with or without siRNA were mixed with 
allogenic CD3
+






 cells) induction by flow 
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Tregs  suppression assay 
To test Tregs function, allogeneic CD3
+
 T cells were labeled by 5 µM 5-(6-) carboxyfluoresceine diacetate 
succinimidyl ester (CFSE; Molecular Probes, Eugene, Oregon, USA) and activated for 2 days in flat-bottom 
96-well microplates (1.5x10
5 
/ well) pre-coated with anti-CD3 mAb (2 mg/ml, clone UCHT1; Bio-Legend) 














Regulatory T-Cell Isolation Kit (Miltenyi Biotec), and after irradiation added to activated CD3
+









 / well) were used as negative control.  After 5 days, T cells were 
harvested and analyzed by FACS.  
 
Determination of IDO1 expression using Real-time PCR  and functional activity 











 DCs by using Qiagen RNeasy microplus kit (Qiagen, Valencia, CA, USA). Then, 0.5 μg of 
RNA was used for retro-transcription with ImProm-II™ Reverse Transcriptase (Promega Corporation) and 
random hexamers (Invitrogen, Carlsbad, CA, USA). IDO1 copy number was evaluated as previously 
described [22]. IDO1 enzyme activity was quantified in terms of ability to catalyze L-tryptophan into 
kynurenine, as described [23].  
 
Western blot analysis 
Cell lysates were separated by SDS-PAGE, transferred onto nitrocellulose membrane (GE Healthcare, UK) 
and then, subjected to Western blotting. Membranes were saturated for 1 h at room temperature in blocking 
buffer (1X PBS, 0.1% Tween 20, 5% non-fat milk) and then, incubated overnight at 4°C with the primary 





-derived DCs were fixed for 2’ in cold acetone and frozen at -20°C. Sections were stained with anti-
Integrin αE (ber-ACT8), known as CD103 and anti-IDO1 (I-17) (Santa Cruz Biotechnology, CA, USA) and, 
7                                                                                    
                                                                                                                
then, counterstained with horse Texas Red-conjugated anti-mouse IgG (Vector Laboratories, CA, USA) and 
FITC-conjugated anti-goat IgG in donkey (Jackson Immuno Research, PA, USA) secondary Abs, 
respectively.
 
Images were collected and processed with a Axiovert 40 CFL (Carl Zeiss Microscopy-LLC, 
NY, United States). The immunofluorescence intensity was measured by densitometry (Adobe Photoshop 
6.0 software) (n =12 randomly selected cells). The values were corrected for the number of pixels to 
compare cells of different size. Cells are grouped in classes of fluorescence intensity (fluorescence intensity 




The results are expressed as the mean ± SD of at least 8 different experiments. The differences were 






 HSPCs give rise to CD1a
+
 DCs which express IDO1 
Preliminarily, IDO1 protein expression in BM, mobilized PB and CB–derived CD34
+
 cells was under the 
detection level (Figure 1A) and no enzymatic activity was observed (data not shown). However, during DC 
differentiation, IDO1 was significantly up-regulated (Figure 1A-C) with a differential expression among 
CD34
+


















DCs  showed increased  IDO1 mRNA (25,366.0 ± 4,727.0 versus 1,400.0 ± 617.0 copies; p = 




 cells expressed IDO1 at very low level (780,0 ± 













 counterparts (60.2 ± 17.4 
versus 9.2 ± 1.1 M; p = 0.02) and, accordingly, the addition of the IDO1-inhibitor 1-MT-L  reduced 




 DCs (60.2 ± 17.4 versus 24.6 ± 9.1 M; p = 0.02) and 
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 counterparts (Figure 1C). These data demonstrate that during DC differentiation from 
CD34
+






















 counterparts as stimulators of allogeneic T-cell proliferation and as inducers of Tregs. Figure 2A 









 cells (fold – change 1.93 ± 0.12 versus 5.99 ±  2.00; p = 0.04). Again, the addition of 1-




DCs were used 
(fold – change 1.93 ± 0.12 versus 3.71 ±  0.51; p = 0.01). A similar pattern was observed as for Tregs 















 counterparts (22.87 % ± 10.38) (p = 0.005) and 




 DCs were used (37.40 
% ± 11.60 % versus 26.40 % ± 12.59 % with and without 1-MT-L, respectively; p = 0.005). In agreement 




DCs are capable of inducing higher number of Tregs 

















 cells,  had inhibitory capacity on T-cell 





















reduce T-cell proliferation and induce bona fide FOXP3
+




DCs express Langerin, CD11b, CD1c and CD103 




 DCs obtained during the 
differentiation of CD34
+









 DCs represented 21% and 36% of the whole cell population, respectively (Figure 
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may be considered as immature DCs, since they expressed co-stimulatory molecules and HLA-DR at 














 DCs, expressed CD1c 
(25.9 ± 12.1 %). As expected [31, 32], Langerin
+




 subset (20.0 ± 













 cells, concomitantly expressed Langerin and 






, which were shown to lack CD14 expression, 
were also negative for the monocyte-linked marker, CD68 (data not shown). 
 
CD103 expression in CD34
+
-derived DCs identifies IDO1-expressing cells 
Gut CD103
+
 DCs have been shown to express IDO1 [33]. We, then, evaluated whether CD103 may identify 
the subset of IDO1-expressing DCs also among CD34
+
-derived DCs. As shown in Figure 4A (upper panel), 
immunofluorescence studies demonstrated that only CD103
+
 cells expressed IDO1 at high level. These data 








 DCs (Figure S6, 
upper panel). Indeed, as shown in Figure 4A (lower panel), the quantification of IDO1 signal intensity 
revealed that in the class of very high intensity (30-40 fluorescence intensity) only CD103
+
 cells, and not 
CD103
-
 cells, could be observed. Moreover, the majority of CD103
+
 cells were located in the class of intense 




 = 4/1) while CD103
-
 cells were mainly 





S6, lower panel). A representative field used for quantification was shown in Figure 4A (upper panel). To 
confirm these data,  CD103
+
 cells were sorted from CD1a
+
 DCs obtained after 7 days of culture and tested 
for IDO1 expression by Western blotting. In agreement with immunofluorescence results, IDO1 protein 
expression was observed in CD103
+
 cells, whereas it was almost absent in their CD103
-
 counterparts (Figure 
4B). 
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 DCs induce Tregs via IDO1 
To investigate the role of IDO1 expression by CD103
+
 DCs on Treg-cell development, we co-cultured IDO1-
expressing CD103
+
 DCs with purified CD3
+
 T cells with or without 1-MT-L. Cell viability after culture with 
1-MT-L was not different from that cultured in medium alone (85.0  7.0 % and 80.0  8.0 %,  respectively), 
as well as CD4/CD8 T cell ratio was not modified by 1-MT-L (data not shown). As shown in Figure 5A, co-
culture of T cells with IDO1-expressing CD103
+







cells as compared to CD3
+
 T cells alone: 22.03  3.84 % versus 4.23  0.76 % (p = 0.002). Although also 
CD103
- 
DCs were capable of inducing Tregs, the addition of 1-MT-L reduced such effect only when IDO1-
expressing CD103
+
 DCs were used (22.03 ± 3.84 % versus 6.80 %; p = 0.01)  and, importantly, to the 
level observed before culture (Figure 5A). Accordingly with recent reports on normal IDO1-expressing Mo-
DCs [17, 18],  these data strongly suggest that IDO1 represents the main mechanism by which CD103
+







 T cells. Conversely, CD103
-
 DCs induce Tregs in a IDO-independent manner. To 
validate  the Tregs nature of the cells induced by IDO1-expressing CD103
+
 DCs, allogeneic CD3
+
 T cells 









obtained from co-culture with CD103
+





 T cells, generated from co-culture with CD103
+
 DCs, were added to cell cultures, as compared 











 T cells induced by IDO1-expressing CD103
+




Human DCs arise from HSPCs and may be divided into different cell subsets, known as conventional or 
“myeloid” DCs and defined by their in vitro cytokine-mediated differentiation pathways [34]. Among these, 
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LCs and DDC-IDCs, which localize to skin epithelia and dermis, respectively, develop in vitro from CD34
+
 
HSPCs upon exposure to a cytokine combination, including GM-CSF and TNF-α [35-37] through an 









 for DDC-IDCs [26]. 




 cells express Langerin, 







 DCs also expresses CD103. CD103-expressing DCs may be found in lymphoid 
and non-lymphoid organs and are derived from BM committed DC progenitors, which give rise to lymphoid 
tissue DCs and non-lymphoid tissue CD103
+
 DCs [5, 38]. In particular, fully mature non-lymphoid CD103
+
 







and in nearly all non-lymphoid tissues, including gut, kidney, lung and liver [5]. At the level of progenitor 
cells, few reports have addressed the expression of CD103 on BM hematopoietic DC precursors, especially 






 DCs has 
not been previously reported and may suggest a specific lineage commitment of a subset of CD34
+
-derived 
DCs, defined by CD103 expression.  
Mature non-lymphoid tissue CD103
+
 DCs are important regulators of the immune response through a dual, 
both activatory and tolerogenic, role in Ag presentation [5]. While they facilitate Ag cross-priming to T cells 
[2, 38],
 
they have been also demonstrated to contribute to the control of inflammation via the conversion of 




Such functional plasticity, which certainly depends on different signals 
to CD103
+
 DCs deriving from tissue microenvironment [39], raises the question of whether, at the level of 
progenitor cells, committed CD103
+
 DCs may have expression pathways corresponding to specific 
functions. Indeed, although some authors have recently demonstrated that the development program of 
human DCs is operated independently of lineage commitment [40],
 
some others suggest that different DC 
subsets, i.e. plasmacytoid DCs [41], possess distinct characteristics and functions as a consequence of a 
different origin. In this scenario, it is noteworthy that fully mature and resident gut CD103
+
 DCs acquire 
tolerogenic functions, thus contributing to oral tolerance induction, via IDO1 expression [33]. In the present 
paper, we demonstrate that among human in vitro generated CD34
+
-derived DCs, CD103 marks a subset of 
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 DCs with a specific expression pathway and function, as defined by IDO1. Given the 
critical role of IDO1 in the regulation of tolerance, we may speculate that at the level of HSPCs, CD103
+
 
DCs are committed to tolerance induction, independently of tissue-derived signals. Accordingly, at the 
functional level, CD103
+
 DCs are in vitro capable of inducing a population of FOXP3
+
 Tregs.  
The in vivo relevance of our in vitro findings needs to be better investigated. Results from BM transplant in 
the mouse model have demonstrated that CD103
+
 non-lymphoid DCs localize to dermis directly from the 
blood stream and are of hematopoietic BM origin [7, 38].
 
Our data characterize a population of human 
hematopoietic origin DCs, expressing CD103, which may act as tolerogenic cells via IDO1 expression. To 
investigate the localization of these cells in vivo, specific experiments in the mouse model and in human skin 
biopsies are highly warranted and are in progress.  
In conclusion, a subset of DCs obtained from human CD34
+
 HSPCs induces Tregs through IDO1. These cells, 





DCs may be intrinsically committed to function as regulatory DCs via IDO1 
expression, which may be part of a tolerogenic signature during DC development.  
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Figure legends 
Figure 1. Expression and enzymatic activity of IDO1. (A) The expression of IDO1 transcript by BM, 
mobilized PB and CB–derived CD34
+

















 DCs were derived only from mobilized 









 DCs. -actin was used as loading control . The results are representative 
of 8 independent experiments. (C) IDO1 enzyme activity was quantified in terms of its ability to catalyze L-
tryptophan into kynurenine. 1-MT-L was used as inhibitor of IDO1 activity. Results represent the mean  
SD of multiple replicates of 8 different experiments.* p  0.05, ** p < 0.03. 
 
Figure 2. T-cell proliferation, Tregs induction and function. (A) CellTiter Proliferation Assay was used to 
evaluate T-cell proliferation. Allogeneic CD3
+ 








 DCs with and without 1-MT-L. Fold change was calculated by using CD3
+
 T cells alone as 






Tregs from allogeneic CD3
+


















 DCs were tested for their capacity to inhibit the proliferation of allogeneic CD3
+
 T cells, previously 
labelled with CFSE. The cell proliferation was evaluated using flow cytometry.  CD3
+
 T cells were activated 
by anti-CD3 and anti-CD28 mAbs. Activated CD3
+
 T cells alone were used as control samples. * p 0.05, 
** p < 0.03. Results represent the mean  SD of multiple replicates of  8 different experiments. D) Silencing 






Tregs from allogeneic CD3
+








 , previously treated with IDO1 siRNA, 
was evaluated. * p 0.05, ** p < 0.03. Results represent the mean  SD of multiple replicates of  3 different 
experiments. 
 
Figure 3. Phenotype of CD34-derived immature DCs. (A) CD1a and CD14 expression in whole culture after 
7 days of CD34
+
 cells differentiation (representative experiment). (B) Surface expression of Langerin and 
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 DCs by using flow cytometry. Results are representative of 8 independent 
experiments. 
 




 DCs.  (A) Immunofluorescence staining of IDO1 
(FITC) and CD103 (Texas Red) in CD34
+
-derived DCs (upper panel). Representative field is used for 





DCs (lower panel). IDO1 fluorescence intensity was measured by densitometry (n=12; randomly selected 
cells). Cells are grouped in classes of fluorescence intensity and plotted relative to CD103 expression. B) 




 DCs. -actin was used as loading control . 
Results are representative of 8 independent experiments. 
 
Figure 5. Induction of  Tregs derived from CD103
+







Tregs from allogeneic CD3
+
 T cells by CD103
+
 DCs was evaluated. 1-MT-L as inhibitor 
was used. CD103
+ 
DCs were purified from CD34
+
-derived immature DCs. Results represent the mean  SD 




T cells derived from CD103
+
 DCs were tested for their capacity 
to inhibit the proliferation of allogeneic CD3
+
 T cells, previously labelled with CFSE. Cell proliferation was 
evaluated by using flow cytometry.  CD3
+
 T cells were activated by anti-CD3 and anti-CD28 mAbs. Results 
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